Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Joern-Peter Halle"'
Autor:
Jacques Moisan, Chunxiao Xu, Amit Deshpande, Joern-Peter Halle, Neil Brewis, Lindsay Webb, Brain Rabinovich, Xueyuan Zhou, Frederic Christian Pipp, Rene Schweickhardt, Sireesha Yalavarthi, Clotilde Bourin, Payel Ghatak, Barroq Safi, Francisca Wollerton, Jose Munoz-Olaya, Natalya Belousova, Marat Alimzhanov, Martina Hubensack, Andree Blaukat
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/ac03000f810b45d7aff318ced96b4000
Autor:
Sneha Berry, Nicolas Giraldo, Peter Nguyen, Benjamin Green, Haiying Xu, Aleksandra Ogurtsova, Abha Soni, Farah Succaria, Daphne Wang, Charles Roberts, Julie Stein, Elizabeth Engle, Drew Pardoll, Robert Anders, Tricia Cottrell, Janis M. Taube, Ben Tran, Mark Voskoboynik, James Kuo, Yung-Lue Bang, Hyun-Cheo Chung, Myung-Ju Ahn, Sang-We Kim, Ayesh Perera, Daniel Freeman, Ikbel Achour, Raffaella Faggioni, Feng Xiao, Charles Ferte, Charlotte Lemech, Funda Meric-Bernstam, Theresa Werner, Stephen Hodi, Wells Messersmith, Nancy Lewis, Craig Talluto, Mirek Dostalek, Aiyang Tao, Sarah McWhirter, Damian Trujillo, Jason Luke, Chunxiao Xu, BoMarelli, Jin Qi, Guozhong Qin, Huakui Yu, Molly Jenkins, Kin-Ming Lo, Joern-Peter Halle, Yan Lan, Matthew Taylor, Nicholas Vogelzang, Allen Cohn, Daniel Stepan, Robert Shumaker, Corina Dutcus, Matthew Guo, Emmett Schmidt, Drew Rasco, Marcia Brose, Christopher Di Simone, Sharad Jain, Donald Richards, Carlos Encarnacion, James Mier, Jeongshin An, Yeun-yeoul Yang, Won-Hee Lee, Jinho Yang, Jong-kyu Kim, Hyun Goo Kim, Se Hyun Paek, Jun Woo Lee, Joohyun Woo, Jong Bin Kim, Hyungju Kwon, Woosung Lim, Nam Sun Paik, Yoon-Keun Kim, Byung-In Moon, Filip Janku, David Tan, Juan Martin-Liberal, Shunji Takahashi, Ravit Geva, Ayca Gucalp, Xueying Chen, Kulandayan Subramanian, Jennifer Mataraza, Jennifer Wheler, Philippe Bedard
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
After publication of this supplement [1, 2], it was brought to our attention that due to an error authors were missing in the following abstracts. This has now been included in this correction.
Externí odkaz:
https://doaj.org/article/5e0fdcdf298e4148a8ad792b96d6446a
Autor:
Dong Zhang, Feng Jiang, Rinat Zaynagetdinov, Hui Huang, Vanita D. Sood, Hong Wang, Xinyan Zhao, Molly H. Jenkins, Qingyong Ji, Youbin Wang, David P. Nannemann, Djordje Musil, John Wesolowski, Andrea Paoletti, Tin Bartholomew, Melissa G. Derner, Qi An, Christel Iffland, Joern-Peter Halle
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
T cell immunoglobulin and mucin domain-3 (TIM-3) is an immune checkpoint that regulates normal immune responses but can be exploited by tumor cells to evade immune surveillance. TIM-3 is primarily expressed on immune cells, particularly on dysfunctio
Externí odkaz:
https://doaj.org/article/f2420cb2a82040deb84b2167b543e3fe
Autor:
Amit Deshpande, Barroq Safi, Martina Hubensack, Lindsay Webb, Rene Schweickhardt, Natalya Belousova, Payel Ghatak, Francisca Wollerton, Joern-Peter Halle, Marat Alimzhanov, Frederic Christian Pipp, Jacques Moisan, Brain Rabinovich, Neil Brewis, Xueyuan Zhou, Andree Blaukat, Chunxiao Xu, Jose Munoz-Olaya, Clotilde Bourin, Sireesha Yalavarthi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundThe costimulatory receptor CD137 (also known as 4-1BB and TNFRSF9) plays an important role in sustaining effective cytotoxic T cell immune responses and its agonism has been investigated as a cancer immunotherapy. In clinical trials, the sy
Autor:
Dong Zhang, Christie A. Kelton, Zhouxiang Chen, Clotilde Bourin, Hong Wang, Sireesha Yalavarthi, Chunxiao Xu, Lindsay Webb, Natalya Belousova, Joern-Peter Halle, Andree Blaukat, Jacques Moisan, Hui Huang, Feng Jiang
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A351-A352
BackgroundM6223 is a fully human antagonistic anti-T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) antibody in IgG1 format with Fc-mediated effector function.MethodsThe ability of M6223 to block the interaction of TIGIT with its li
Autor:
Chunxiao Xu, Sireesha Yalavarthi, Clotilde Bourin, Christie Kelton, Joern-Peter Halle, Jacques Moisan
Publikováno v:
Cancer Research. 82:593-593
Background: T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) is an inhibitory receptor expressed on lymphocytes and has recently emerged as a target in cancer immunotherapy. M6223 is a fully
Autor:
Molly H. Jenkins, Vanita D. Sood, Feng Jiang, Christel Iffland, An Qi, Hui Huang, Xinyan Zhao, Joern-Peter Halle, Qingyong Ji, Hong Wang, Melissa G Derner, Dong Zhang, John S. Wesolowski, Djordje Musil, Andrea Paoletti, Rinat Zaynagetdinov, Tin Bartholomew, D.P. Nannemann, Youbin Wang
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Oncoimmunology
Oncoimmunology
T cell immunoglobulin and mucin domain-3 (TIM-3) is an immune checkpoint that regulates normal immune responses but can be exploited by tumor cells to evade immune surveillance. TIM-3 is primarily expressed on immune cells, particularly on dysfunctio
Autor:
Ewen Sedman, Joern-Peter Halle, Dietmar Gross, Luciano Rossetti, Mark R. Trusheim, Bruno Osterwalder, Janet Ogden, Hugues Dolgos
Publikováno v:
Drug Discovery Today. 21:517-526
Merck is implementing a question-based Translational Medicine Guide (TxM Guide) beginning as early as lead optimization into its stage-gate drug development process. Initial experiences with the TxM Guide, which is embedded into an integrated develop
Autor:
Andree Blaukat, Marat Alimzhanov, Frank Zenke, Christiane Amendt, Patricia Soulard, Ashwin George, Joern-Peter Halle, Astrid Zimmerman, Parantu K. Shah, Andreas Schroeder, Martin H. Falk
Publikováno v:
Cancer Research. 80:964-964
Ataxia-telangiectasia mutated and Rad3-related kinase (ATR) is one of the key players in the DNA damage response (DDR) to replication stress. M6620 is a potent and selective ATR inhibitor which has been shown to sensitize cancer cells to the lethal e
Autor:
Marat Alimzhanov, Patricia Soulard, Astrid Zimmermann, Andreas Schroeder, Keyvan Tadjalli Mehr, Christiane Amendt, Geok Choo Sim, Andree Blaukat, Joern-Peter Halle, Frank T. Zenke
Publikováno v:
Cancer Research. 79:2269-2269
Recently, combination of checkpoint inhibitors with chemotherapy demonstrated significant improvement of overall survival (OS) and progression-free survival (PFS) compared with chemotherapy alone in patients with metastatic non-squamous and squamous